Status:
COMPLETED
Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients
Lead Sponsor:
Stanford University
Conditions:
Cerebrovascular Accident
Moyamoya Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya disease and stroke patients
Detailed Description
In the early hours following large vessel occlusion, the ultimate severity of the stroke is largely determined by the ability of collateral flow networks to supply blood to ischemic tissue via circuit...
Eligibility Criteria
Inclusion
- Moyamoya Patient
- Men and non-pregnant women, at least 21 years of age.
- Outpatients seen at the Stanford Neurosurgery and Neurology Departments.
- Ability to comply with all studies.
- Inclusion of Moyamoya patients with Sulfa allergies.
- Patients diagnosed with or suspected to have Moyamoya disease.
- Stroke Patient
- Men and non-pregnant women, at least 21 years of age.
- Patients admitted to the inpatient Stanford Stroke Service for stroke-like symptoms, less than 24 hours from last time seen normal.
- Ability to comply with all studies.
- Clinical Patient Acetazolamide MRI
- Men and non-pregnant women, at least 21 years of age.
- Patients admitted to the inpatient Stanford Stroke Service or Neurosurgical -Service for symptoms compatible with cerebrovascular disease.
- Ability to comply with all studies.
- Normal Subject
- Ability to comply with the MRI study.
Exclusion
- Level of consciousness score of 2 or greater as defined by the NIH stroke scale.
- Symptoms likely related to psychoactive drugs or patients with symptoms related to an active inflammatory disease such as AIDS, meningitis, or cerebritis.
- Psychiatric or substance abuse disorder or dementia that interferes with evaluation or interpretation of the neurologic and mental assessment of these patients.
- Informed consent cannot be obtained either from the patient or legal representative.
- Severe coexisting or terminal systemic disease that limits life expectancy or that may interfere with the conduct of the study.
- Symptoms related to an alternative diagnosis such as seizures or migraine.
- Patients receiving any thrombolytic agent or receiving acute stroke investigational drug therapies during the 30-day study.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT01419275
Start Date
April 1 2009
End Date
November 1 2013
Last Update
August 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305